Use of the brain parenchymal fraction to measure whole brain atrophy in relapsing-remitting MS
Abstract
Background: Episodic inflammation in the CNS during the early stages of MS results in progressive disability years later, presumably due to myelin and axonal injury. MRI demonstrates ongoing disease activity during the early disease stage, even in some patients who are stable clinically. The optimal MRI measure for the destructive pathologic process is uncertain, however.
Methods: In this post-hoc study, MRI scans were analyzed from patients with relapsing MS participating in a placebo-controlled trial of interferon β-1a. The brain parenchymal fraction, defined as the ratio of brain parenchymal volume to the total volume within the brain surface contour, was used to measure whole brain atrophy. The relationship between disease features and brain atrophy and effect of interferon β-1a were determined.
Results: MS patients had significant brain atrophy that worsened during each of 2 years of observation. In many patients, brain atrophy worsened without clinical disease activity. Baseline clinical and MRI abnormalities were not strongly related to the rate of brain atrophy during the subsequent 2 years. Treatment with interferon β-1a resulted in a reduction in brain atrophy progression during the second year of the clinical trial.
Conclusions: Patients with relapsing-remitting MS have measurable amounts of whole brain atrophy that worsens yearly, in most cases without clinical manifestations. The brain parenchymal fraction is a marker for destructive pathologic processes ongoing in relapsing MS patients, and appears useful in demonstrating treatment effects in controlled clinical trials.
Get full access to this article
View all available purchase options and get full access to this article.
References
1.
Simon JH. Contrast-enhanced MR imaging in the evaluation of treatment response and prediction of outcome in multiple sclerosis. J Magn Reson Imaging 1997;7:29–37.
2.
McFarland HF, Stone LA, Calabresi PA, Maloni H, Bash CN, Frank JA. MRI studies of multiple sclerosis: implications for the natural history of the disease and for monitoring effectiveness of experimental therapies. Mult Scler 1996;2:198–205.
3.
McFarland HF, Frank JA, Albert PS, et al. Using gadolinium-enhanced magnetic resonance imaging lesions to monitor disease activity in multiple sclerosis. Ann Neurol 1992;32:758–766.
4.
Filippi M, Horsfield MA, Morrissey SP, et al. Quantitative brain MRI lesion load predicts the course of clinically isolated syndromes suggestive of multiple sclerosis. Neurology 1994;44:635–641.
5.
Arnold DL, Riess GT, Matthews PM, et al. Use of proton magnetic resonance spectroscopy for monitoring disease progression in multiple sclerosis. Ann Neurol 1994;36:76–82.
6.
Trapp BD, Peterson J, Ransohoff RM, Rudick R, Mork S, Bo L. Axonal transection in the lesions of multiple sclerosis. N Engl J Med 1998;338:278–285.
7.
Simon JH, Jacobs LD, Campion M, et al. A longitudinal study of brain atrophy in relapsing MS. Neurology 1999;53:139–148.
8.
The IFNB Study Group.Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993;43:655–661.
9.
Paty DW, Li DK, UBC MS/MRI Study Group, The IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993;43:662–667.
10.
Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol 1996;39:285–294.
11.
PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group.Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. Lancet 1998;352:1498–1504.
12.
Jacobs L, Cookfair DL, Rudick RA, et al. A phase III trial of intramuscular recombinant beta interferon as treatment for exacerbating-remitting multiple sclerosis: design and conduct of study and baseline characteristics of patients. Mult Scler 1995;1:118–135.
13.
Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983;33:1444–1452.
14.
Simon JH, Jacobs LD, Campion M, et al. Magnetic resonance studies of intramuscular interferon beta-1a for relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group. Ann Neurol 1998;43:79–87.
15.
Fisher E, Cothren RM, Tkach JA, Masaryk TJ, Cornhill JF. Knowledge-based 3D segmentation of MR images for quantitative MS lesion tracking. SPIE Med Imag 1997;3034:599–610.
16.
Filippi M, Colombo B, Rovaris M, Pereira C, Martinelli V, Comi G. A longitudinal magnetic resonance imaging study of the cervical cord in multiple sclerosis. J Neuroimaging 1997;7:78–80.
17.
Losseff NA, Wang L, Lai HM, et al. Progressive cerebral atrophy in multiple sclerosis. A serial MRI study. Brain 1996;119:2009–2019.
18.
Losseff NA, Webb SL, O’Riordan JI, et al. Spinal cord atrophy and disability in multiple sclerosis: a new reproducible and sensitive MRI method with potential to monitor disease progression. Brain 1996;119:701–708.
19.
Simon JH, Schiffer RB, Rudick RA, Herndon RM. Quantitative determination of MS-induced corpus callosum atrophy in vivo using MR imaging. Am J Neuroradiol 1987;8:599–604.
20.
Cover KS, Petkau J, Paty DW. Lesion load reproducibility and statistical sensitivity of clinical trials in multiple sclerosis. Neurology 1999;52:433–434.
21.
Trapp BD, Ransohoff RM, Fisher E, Rudick RA. Neurodegeneration in multiple sclerosis: relationship to neurological disability. The Neuroscientist 1999;5:48–57.
22.
Cook RD, Wisniewski HM. The role of oligodendroglia and astroglia in Wallerian degeneration of the optic nerve. Brain Res 1973;61:191–206.
Information & Authors
Information
Published In
Neurology®
Volume 53 • Number 8 • November 1, 1999
Pages: 1698
Copyright
© 1999.
Publication History
Received: March 24, 1999
Accepted: June 11, 1999
Published online: November 1, 1999
Published in print: November 1, 1999
Authors
Metrics & Citations
Metrics
Citations
Download Citations
If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Select your manager software from the list below and click Download.
Cited By
- Orchestrating a New Path for Multiple Sclerosis: Achieving Physical, Cognitive, and Emotional Rehabilitation Goals Through Physical and Music Therapy, International Journal of MS Care, 25, 4, (168-175), (2023).https://doi.org/10.7224/1537-2073.2021-144
- Learning from pseudo-labels: deep networks improve consistency in longitudinal brain volume estimation, Frontiers in Neuroscience, 17, (2023).https://doi.org/10.3389/fnins.2023.1196087
- The use of magnetic resonance imaging in the diagnosis and long-term management of multiple sclerosis, Neurology, 63, 11_suppl_5, (S3-S11), (2023)./doi/10.1212/WNL.63.11_suppl_5.S3
- Selecting a disease-modifying agent as platform therapy in the long-term management of multiple sclerosis, Neurology, 63, 11_suppl_5, (S19-S27), (2023)./doi/10.1212/WNL.63.11_suppl_5.S19
- Interferon beta-1a as an investigational treatment for CIDP, Neurology, 60, 8_suppl_3, (S23-S28), (2023)./doi/10.1212/WNL.60.8_suppl_3.S23
- The pathogenesis of CIDP, Neurology, 60, 8_suppl_3, (S2-S7), (2023)./doi/10.1212/WNL.60.8_suppl_3.S2
- Methylprednisolone effect on brain volume and enhancing lesions in MS before and during IFNβ-1b, Neurology, 59, 5, (688-694), (2023)./doi/10.1212/WNL.59.5.688
- Disease modifying therapies in multiple sclerosis, Neurology, 59, 3, (471-473), (2023)./doi/10.1212/WNL.59.3.471
- Randomized controlled trials to assess therapies for multiple sclerosis, Neurology, 58, 8_suppl_4, (S40-S48), (2023)./doi/10.1212/WNL.58.8_suppl_4.S40
- MRI in the diagnosis and management of multiple sclerosis, Neurology, 58, 8_suppl_4, (S23-S31), (2023)./doi/10.1212/WNL.58.8_suppl_4.S23
- See more
Loading...
View Options
Get Access
Login options
Check if you have access through your login credentials or your institution to get full access on this article.
Personal login Institutional LoginPurchase Options
Purchase this article to get full access to it.